Olaparib - Uses, Dosage, Side Effects, Interactions

Olaparib is a small molecule inhibitor of poly ADP-ribose polymerase and is used as an antineoplastic agent in the therapy of refractory and advanced ovarian carcinoma. Olaparib therapy is associated with a low rate of transient elevations in serum aminotransferase during therapy and has not been linked to instances of clinically apparent liver injury.

Olaparib is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single-strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.

Olaparib is a member of the class of N-acyl piperazines obtained by formal condensation of the carboxy group of 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoic acid with the free amino group of N-(cyclpropylcarbonyl)piperazine; used to treat advanced ovarian cancer. It has a role as an antineoplastic agent, an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor, and an apoptosis inducer. It is an N-acyl piperazine, a member of cyclopropanes, a member of monofluorobenzenes, and a member of phthalazines.

Olaparib is used to treat a number of BRCA-associated tumors, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.

Mechanism of Action

Poly(ADP-ribose) polymerases (PARPs) are multifunctional enzymes comprising 17 members. They are involved in essential cellular functions, such as DNA transcription and DNA repair. PARPs recognize and repair cellular DNA damage, such as single-strand breaks (SSBs) and double-strand breaks (DSBs). Different DNA repair pathways exist to repair these DNA damages, including the base excision repair (BER) pathway for SSBs and BRCA-dependent homologous recombination for DSBs. Olaparib is a PARP inhibitor: while it acts on PARP1, PARP2, and PARP3, olaparib is a more selective competitive inhibitor of NAD⁺ at the catalytic site of PARP1 and PARP2. Inhibition of the BER pathway by olaparib leads to the accumulation of unrepaired SSBs, which leads to the formation of DSBs, which is the most toxic form of DNA damage. While BRCA-dependent homologous recombination can repair DSBs in normal cells, this repair pathway is defective in cells with BRCA1/2 mutations, such as certain tumor cells. Inhibition of PARP in cancer cells with BRCA mutations leads to genomic instability and apoptotic cell death. This end result is also referred to as synthetic lethality, a phenomenon where the combination of two defects – inhibition of PARP activity and loss of DSB repair by HR – that are otherwise benign when alone, leads to detrimental results. _In vitro_ studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death.

Olaparib is a cytotoxic and anti-tumor agent. Olaparib inhibits the growth of selective tumor cell lines _in vitro_ and decreases tumor growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. The drug exerts anti-tumour effects in cell lines and mouse tumor models with deficiencies in BRCA1/2, ATM, or other genes involved in the homologous recombination repair (HRR) of DNA damage and correlated with platinum response. In preclinical models of cancer, olaparib demonstrated anti-tumor activity when used alone, in combination with chemotherapeutic agents, or radiotherapy. Olaparib can act as a chemosensitizer to potentiate the cytotoxicity of DNA-damaging chemotherapeutic agents such as alkylating agents and platinum-based drugs. It can also act as a radiosensitizer by preventing PARP-mediated DNA repair.

Indications

**Ovarian cancer** – Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib is indicated in combination with [bevacizumab] for the maintenance treatment of adults with an advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
**Breast cancer** – Olaparib is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious g_BRCA_m human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib is indicated for the treatment of adult patients with deleterious or suspected deleterious g_BRCA_m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR) positive breast cancer should have been treated with prior endocrine therapy or be considered inappropriate for endocrine therapy. **Pancreatic cancer** Olaparib is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. **Prostate cancer** Olaparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a hormone agent, such as [enzalutamide] or [abiraterone].
* Ovarian cancer – Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy maintenance treatment of adult patients with platinum-sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.
* Breast cancer – Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with anthracycline and taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.
* Adenocarcinoma of the pancreas – Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.
* Prostate cancer – Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
Advanced ovarian carcinoma – Olaparib is a small molecule inhibitor of poly ADP-ribose polymerase and is used as an antineoplastic agent in the therapy of refractory and advanced ovarian carcinoma.
Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.
Advanced Epithelial Ovarian Cancer
Advanced Fallopian Tube Carcinoma
Advanced Primary Peritoneal Carcinoma
Early Breast Cancer
Metastatic Breast Cancer
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Pancreatic Adenocarcinoma Metastatic
Recurrent Epithelial Ovarian Cancer
Recurrent Fallopian Tube Cancer
Recurrent platinum-sensitive primary peritoneal cancer
Maintenance therapy

Use in Cancer

Olaparib is approved to treat:

Breast cancer is HER2 negative and has certain germline mutations in the BRCA1 or BRCA2 gene. It is used after surgery in adults with:
- High-risk early-stage breast cancer that has been treated with chemotherapy before or after surgery.
- Metastatic cancer has been treated with chemotherapy before or after the cancer spread.
The ovarian epithelial, fallopian tube, or primary peritoneal cancer. Olaparib is used as maintenance therapy in adults who are having a complete or partial response to platinum chemotherapy. It is used:
- As the first maintenance therapy in patients with advanced cancer that has certain germline or somatic mutations in the BRCA1 or BRCA2 gene.
- Bevacizumab as the first maintenance therapy in patients with advanced cancer that has genomic instability and/or certain germline or somatic mutations in the BRCA1 or BRCA2 gene.
- In patients with recurrent cancer.
Pancreatic cancer. Olaparib is used as maintenance therapy in adults with metastatic cancer that has not progressed after first-line therapy with platinum chemotherapy and has certain germline mutations in the BRCA1 or BRCA2 gene.
Prostate cancer that is metastatic, has germline or somatic mutations in certain genes involved in the homologous recombination repair pathway, and is castrate-resistant (has not responded to treatments that lower testosterone levels). Olaparib is used in adults whose cancer has gotten worse after treatment with enzalutamide or abiraterone.

Olaparib is also being studied in the treatment of other types of cancer.

Contraindications

acute myeloid leukemia, a type of blood cancer
a type of inflammation of the lung called interstitial pneumonitis
myelodysplastic syndrome, a bone marrow disorder
pregnancy
a patient who is producing milk and breastfeeding
chronic kidney disease stage 3A (moderate)
chronic kidney disease stage 3B (moderate)

Dosage

Strengths: 50 mg; 100 mg; 150 mg

Breast Cancer

FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:

300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years

FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:

300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years
When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.

RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION RESISTANT PROSTATE CANCER:

300 mg orally 2 times a day until disease progression or unacceptable toxicity
Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen.
Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy.
Refer to the prescribing Information for bevacizumab when used in combination with this drug for more information.
BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability
MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy
ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy
GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy
FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone

Prostate Cancer

FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:

300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years

FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:

300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years
When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.

RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:

300 mg orally 2 times a day until disease progression or unacceptable toxicity
Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen.
Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy.
Refer to the prescribing information for bevacizumab when used in combination with this drug for more information.
BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with an advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability
MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy
ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy
GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy
FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone

Ovarian Cancer

FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:

300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years

FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:

300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years
When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.

RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:

300 mg orally 2 times a day until disease progression or unacceptable toxicity
Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen.
Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy.
Refer to the prescribing information for bevacizumab when used in combination with this drug for more information.
BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability
MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy
ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy
GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy
FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone

Fallopian Tube Cancer

FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:

300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years

FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:

300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 year
When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.

RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:

300 mg orally 2 times a day until disease progression or unacceptable toxicity
Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen.
Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy.
Refer to the prescribing information for bevacizumab when used in combination with this drug for more information.
BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability
MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy
ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy
GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy
FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone

Peritoneal Cancer

FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:

300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years

FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:

300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years
When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.

RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:

300 mg orally 2 times a day until disease progression or unacceptable toxicity
Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen.
Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy.
Refer to the prescribing information for bevacizumab when used in combination with this drug for more information.
BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with an advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability
MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with a recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy
ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy
GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine therapy or be considered inappropriate for endocrine therapy
FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone

You Might Also Read Diazepam; Uses, Dosage, Side Effects, Interactions, Pregnancy

Dose Adjustments

FIRST DOSE REDUCTION: 250 mg orally 2 times a day
SECOND DOSE REDUCTION: 200 mg orally 2 times a day

CYP450 3A inhibitors Avoid concomitant use of this drug with CYP450 3A inhibitors and consider alternative agents. If concomitant use cannot be avoided:

Reduce dose to 150 mg orally 2 times a day when used with moderate CYP450 3A inhibitor.
Reduce dose to 100 mg orally 2 times a day when used with strong CYP450 3A inhibitor.

Administration advice:

This drug may be taken with or without food.
The 100-mg tablet is available for dose reduction.
Swallow tablets whole; do not chew, crush, dissolve, or divide.
Advise patients to avoid grapefruit, grapefruit juice, and Seville oranges during treatment as they may increase the level of this drug in the blood.
If a patient misses a dose, instruct them to take their next dose at its scheduled time.

Side Effects

The Most Common

nausea
vomiting
diarrhea
constipation
heartburn
headache
decreased appetite
muscle, joint, or back pain
fatigue
dizziness
stomach pain or discomfort
taste changes
mouth pain or sores
rash
shortness of breath, new or worsening cough, difficulty breathing, wheezing, or fever
weakness
extreme tiredness
weight loss
unusual bruising or bleeding
pale skin
blood in urine or stool
fever, chills, cough, sore throat, difficulty urinating, pain when urinating, or other signs of infection
pain, tenderness, redness, or swelling in one leg
chest pain or tightness; shortness of breath; coughing up blood; or rapid breathing

More common

Black, tarry stools
bladder pain
bleeding gums
bloody or cloudy urine
body aches or pain
chest pain or tightness
chills
cough
cough producing mucus
diarrhea
difficult, burning, or painful urination
ear congestion or pain
fast, pounding, or irregular heartbeat or pulse
fever
frequent urge to urinate
general feeling of discomfort or illness
head congestion
headache
hoarseness or other voice changes
joint pain
loss of appetite
loss of voice
lower back or side pain
muscle aches and pains
nausea
pain or swelling in the arms or legs
painful or difficult urination
pale skin
pinpoint red spots on the skin
rapid shallow breathing
runny or stuffy nose
shivering
sneezing
sore throat
sores, ulcers, or white spots on the lips or in the mouth
sweating
swollen glands
trouble sleeping
trouble breathing
unusual bleeding or bruising
unusual tiredness or weakness
vomiting

Rare

Hives, itching, skin rash
irritation
joint stiffness or swelling
redness of the skin
swelling of the eyelids, face, lips, hands, or feet
trouble swallowing
Back pain
belching
blistering, crusting, irritation, itching, or reddening of the skin
blurred vision
burning, numbness, tingling, or painful sensations
constipation
cracked, dry, or scaly skin
decreased appetite
diarrhea
difficulty with moving
dizziness
dry mouth
fear or nervousness
flushed, dry skin
fruit-like breath odor
heartburn
increased hunger
increased thirst
increased urination
indigestion
lack or loss of strength
loss of bladder control
loss of or change in taste
muscle stiffness
stomach discomfort, upset, or pain
swelling or inflammation of the mouth
unexplained weight loss
unsteadiness or awkwardness
weakness in the arms, hands, legs, or feet

Drug Interactions

DRUG	INTERACTION
Abametapir	The serum concentration of Olaparib can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Olaparib can be increased when combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Olaparib.
Abemaciclib	The metabolism of Abemaciclib can be decreased when combined with Olaparib.
Acalabrutinib	The metabolism of Acalabrutinib can be decreased when combined with Olaparib.
Acenocoumarol	The serum concentration of Acenocoumarol can be increased when it is combined with Olaparib.
Acetaminophen	The metabolism of Olaparib can be increased when combined with Acetaminophen.
Acetazolamide	The metabolism of Olaparib can be decreased when combined with Acetazolamide.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Olaparib.
Adalimumab	The metabolism of Olaparib can be increased when combined with Adalimumab.
Adenovirus type	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Olaparib.
Albendazole	The metabolism of Olaparib can be decreased when combined with Albendazole.
Aldesleukin	The metabolism of Olaparib can be decreased when combined with Aldesleukin.
Alectinib	The metabolism of Alectinib can be decreased when combined with Olaparib.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Olaparib.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olaparib.
Alfentanil	The metabolism of Olaparib can be decreased when combined with Alfentanil.
Alfuzosin	The metabolism of Alfuzosin can be decreased when combined with Olaparib.
Allogeneic process	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Olaparib.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Olaparib.
Alpelisib	The metabolism of Olaparib can be increased when combined with Alpelisib.
Alprazolam	The metabolism of Alprazolam can be decreased when combined with Olaparib.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Olaparib.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Olaparib.
Ambrisentan	The metabolism of Olaparib can be decreased when combined with Ambrisentan.
Aminoglutethimide	The metabolism of Olaparib can be increased when combined with Aminoglutethimide.
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Olaparib.
Amiodarone	The metabolism of Olaparib can be decreased when combined with Amiodarone.
Amitriptyline	The metabolism of Olaparib can be decreased when combined with Amitriptyline.
Amobarbital	The metabolism of Olaparib can be increased when combined with Amobarbital.
Amprenavir	The metabolism of Olaparib can be decreased when combined with Amprenavir.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Olaparib.
Anagrelide	The risk or severity of bleeding can be increased when Anagrelide is combined with Olaparib.
Anakinra	The metabolism of Olaparib can be increased when combined with Anakinra.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Olaparib.
Anifrolumab	The risk or severity of adverse effects can be increased when Olaparib is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Olaparib.
Anthrax immune	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Olaparib.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Olaparib.
Antilymphocyte	The risk or severity of adverse effects can be increased when Olaparib is combined with Antilymphocyte immunoglobulin (horse).
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Olaparib.
Antithrombin III	The risk or severity of bleeding can be increased when Antithrombin III human is combined with Olaparib.
Antithymocyte	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olaparib.
Apalutamide	The metabolism of Olaparib can be increased when combined with Apalutamide.
Apixaban	The metabolism of Olaparib can be decreased when combined with Apixaban.
Apomorphine	The metabolism of Olaparib can be decreased when combined with Apomorphine.
Apremilast	The metabolism of Olaparib can be increased when combined with Apremilast.
Aprepitant	The metabolism of Olaparib can be decreased when combined with Aprepitant.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Olaparib.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Olaparib.
Aripiprazole	The metabolism of Aripiprazole can be decreased when combined with Olaparib.
Aripiprazole la	The metabolism of Aripiprazole lauroxil can be decreased when combined with Olaparib.
Armodafinil	The metabolism of Olaparib can be increased when combined with Armodafinil.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Olaparib.
Artemether	The metabolism of Olaparib can be decreased when combined with Artemether.
Articaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Articaine.
Asciminib	The serum concentration of Olaparib can be increased when it is combined with Asciminib.
Astemizole	The metabolism of Astemizole can be decreased when combined with Olaparib.
AstraZeneca COVID	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Olaparib.
Asunaprevir	The metabolism of Olaparib can be increased when combined with Asunaprevir.
Atazanavir	The metabolism of Olaparib can be decreased when combined with Atazanavir.
Atorvastatin	The metabolism of Atorvastatin can be decreased when combined with Olaparib.
Avacopan	The metabolism of Olaparib can be decreased when combined with Avacopan.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Olaparib.
Axitinib	The metabolism of Axitinib can be decreased when combined with Olaparib.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Olaparib.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Olaparib.
Azelastine	The metabolism of Olaparib can be decreased when combined with Azelastine.
Azithromycin	The metabolism of Olaparib can be decreased when combined with Azithromycin.
Bacillus	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Olaparib.
Bacillus calmette	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Olaparib.
Bacillus cal	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Olaparib.
Baricitinib	The risk or severity of adverse effects can be increased when Olaparib is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Olaparib.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Olaparib.
Beclomethasone d	The metabolism of Olaparib can be increased when combined with Beclomethasone dipropionate.
Belatacept	The risk or severity of adverse effects can be increased when Belatacept is combined with Olaparib.
Belimumab	The risk or severity of adverse effects can be increased when Belimumab is combined with Olaparib.
Belinostat	The risk or severity of adverse effects can be increased when Belinostat is combined with Olaparib.
Belumosudil	The risk or severity of adverse effects can be increased when Olaparib is combined with Belumosudil.
Belzutifan	The serum concentration of Olaparib can be decreased when it is combined with Belzutifan.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Olaparib.
Bendamustine	The risk or severity of adverse effects can be increased when Bendamustine is combined with Olaparib.
Bendroflumet	The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Olaparib.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Benzocaine.
Benzthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Olaparib.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Benzyl alcohol.
Berotralstat	The metabolism of Olaparib can be decreased when combined with Berotralstat.
Betamethasone	The metabolism of Olaparib can be increased when combined with Betamethasone.
Betamethasone p	The metabolism of Olaparib can be increased when combined with Betamethasone phosphate.
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Olaparib.
Bexarotene	The metabolism of Olaparib can be increased when combined with Bexarotene.
Bicalutamide	The metabolism of Olaparib can be decreased when combined with Bicalutamide.
Bifonazole	The metabolism of Olaparib can be decreased when combined with Bifonazole.
Bimekizumab	The metabolism of Olaparib can be increased when combined with Bimekizumab.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Olaparib.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Olaparib.
Blinatumomab	The risk or severity of adverse effects can be increased when Blinatumomab is combined with Olaparib.
Boceprevir	The metabolism of Olaparib can be decreased when combined with Boceprevir.

Bortezomib	The metabolism of Bortezomib can be decreased when combined with Olaparib.
Bosentan	The metabolism of Olaparib can be increased when combined with Bosentan.
Bosutinib	The metabolism of Bosutinib can be decreased when combined with Olaparib.
Brentuximab ve	The metabolism of Brentuximab vedotin can be decreased when combined with Olaparib.
Brigatinib	The metabolism of Brigatinib can be decreased when combined with Olaparib.
Brodalumab	The risk or severity of adverse effects can be increased when Olaparib is combined with Brodalumab.
Budesonide	The metabolism of Olaparib can be increased when combined with Budesonide.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Bupivacaine.
Buprenorphine	The metabolism of Olaparib can be decreased when combined with Buprenorphine.
Buspirone	The metabolism of Olaparib can be decreased when combined with Buspirone.
Busulfan	The metabolism of Busulfan can be decreased when combined with Olaparib.
Butacaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Butacaine.
Butalbital	The metabolism of Olaparib can be increased when combined with Butalbital.
Butamben	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Butamben.
Cabazitaxel	The metabolism of Cabazitaxel can be decreased when combined with Olaparib.
Cabergoline	The metabolism of Cabergoline can be decreased when combined with Olaparib.
Calcitriol	The metabolism of Olaparib can be increased when combined with Calcitriol.
Canakinumab	The metabolism of Olaparib can be increased when combined with Canakinumab.
Candicidin	The metabolism of Olaparib can be decreased when combined with Candicidin.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Olaparib.
Cannabidiol	The metabolism of Olaparib can be decreased when combined with Cannabidiol.
Capecitabine	The risk or severity of adverse effects can be increased when Capecitabine is combined with Olaparib.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Olaparib.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Capsaicin.
Carbamazepine	The metabolism of Olaparib can be increased when combined with Carbamazepine.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Olaparib.
Carfilzomib	The risk or severity of adverse effects can be increased when Carfilzomib is combined with Olaparib.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Olaparib.
Cefradine	The metabolism of Olaparib can be increased when combined with Cefradine.
Cenobamate	The serum concentration of Olaparib can be decreased when it is combined with Cenobamate.
Cephalexin	The metabolism of Olaparib can be decreased when combined with Cephalexin.
Ceritinib	The metabolism of Olaparib can be decreased when combined with Ceritinib.
Cerivastatin	The metabolism of Olaparib can be increased when combined with Cerivastatin.
Certolizumab pegol	The metabolism of Olaparib can be increased when combined with Certolizumab pegol.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Olaparib.
Chloramphenicol	The metabolism of Olaparib can be decreased when combined with Chloramphenicol.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Chloroprocaine.
Chloroquine	The metabolism of Olaparib can be decreased when combined with Chloroquine.
Chlorothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Olaparib.
Chlorpheniramine	The metabolism of Olaparib can be decreased when combined with Chlorpheniramine.
Chlorpromazine	The metabolism of Olaparib can be increased when combined with Chlorpromazine.
Ciclesonide	The risk or severity of adverse effects can be increased when Ciclesonide is combined with Olaparib.
Cilostazol	The metabolism of Cilostazol can be decreased when combined with Olaparib.
Cimetidine	The metabolism of Olaparib can be decreased when combined with Cimetidine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Cinchocaine.
Ciprofloxacin	The metabolism of Olaparib can be decreased when combined with Ciprofloxacin.
Cisapride	The metabolism of Olaparib can be decreased when combined with Cisapride.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Olaparib.
Citalopram	The metabolism of Olaparib can be decreased when combined with Citalopram.
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Olaparib.
Clarithromycin	The metabolism of Olaparib can be decreased when combined with Clarithromycin.
Clevidipine	The metabolism of Olaparib can be increased when combined with Clevidipine.
Clindamycin	The metabolism of Olaparib can be decreased when combined with Clindamycin.
Clobazam	The metabolism of Olaparib can be increased when combined with Clobazam.
Clobetasol pro	The metabolism of Olaparib can be increased when combined with Clobetasol propionate.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Olaparib.
Clofazimine	The metabolism of Olaparib can be decreased when combined with Clofazimine.
Clofibrate	The metabolism of Olaparib can be increased when combined with Clofibrate.
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Olaparib.
Clonidine	The metabolism of Clonidine can be decreased when combined with Olaparib.
Clopidogrel	The metabolism of Olaparib can be decreased when combined with Clopidogrel.
Clostridium t	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Olaparib.
Clozapine	The metabolism of Olaparib can be decreased when combined with Clozapine.
Cobicistat	The metabolism of Olaparib can be decreased when combined with Cobicistat.
Cobimetinib	The metabolism of Cobimetinib can be decreased when combined with Olaparib.
Cocaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Cocaine.
Colchicine	The metabolism of Colchicine can be decreased when combined with Olaparib.
Conivaptan	The metabolism of Olaparib can be decreased when combined with Conivaptan.
Copanlisib	The metabolism of Copanlisib can be decreased when combined with Olaparib.
Corticotropin	The metabolism of Olaparib can be increased when combined with Corticotropin.
Cortisone acetate	The metabolism of Olaparib can be increased when combined with Cortisone acetate.
Corynebacterium	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Olaparib.
Crizotinib	The metabolism of Olaparib can be decreased when combined with Crizotinib.
Curcumin	The metabolism of Olaparib can be decreased when combined with Curcumin.
Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Olaparib.
Cyclopenthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Olaparib.
Cyclophosphamide	The metabolism of Olaparib can be increased when combined with Cyclophosphamide.
Cyclosporine	Olaparib may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Olaparib.
Cyproterone acetate	The metabolism of Olaparib can be decreased when combined with Cyproterone acetate.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Olaparib.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Olaparib.
Dabigatran etexilate	The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Olaparib.
Dabrafenib	The serum concentration of Olaparib can be decreased when it is combined with Dabrafenib.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Olaparib.
Daclatasvir	The metabolism of Olaparib can be decreased when combined with Daclatasvir.
Dacomitinib	The metabolism of Dacomitinib can be decreased when combined with Olaparib.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Olaparib.
Dalfopristin	The metabolism of Olaparib can be decreased when combined with Dalfopristin.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Olaparib.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Olaparib.
Danazol	The metabolism of Olaparib can be decreased when combined with Danazol.
Dapsone	The metabolism of Olaparib can be decreased when combined with Dapsone.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Olaparib.
Darunavir	The serum concentration of Olaparib can be increased when it is combined with Darunavir.
Dasatinib	The metabolism of Olaparib can be decreased when combined with Dasatinib.
Daunorubicin	The metabolism of Olaparib can be decreased when combined with Daunorubicin.
Decitabine	The risk or severity of adverse effects can be increased when Decitabine is combined with Olaparib.
Deferasirox	The metabolism of Olaparib can be increased when combined with Deferasirox.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Olaparib.

Deflazacort	The metabolism of Olaparib can be increased when combined with Deflazacort.
Delavirdine	The metabolism of Olaparib can be decreased when combined with Delavirdine.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Olaparib.
Desipramine	The metabolism of Olaparib can be decreased when combined with Desipramine.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Olaparib.
Desoximetasone	The risk or severity of adverse effects can be increased when Desoximetasone is combined with Olaparib.
Desvenlafaxine	The metabolism of Olaparib can be decreased when combined with Desvenlafaxine.
Deucravacitinib	The risk or severity of adverse effects can be increased when Olaparib is combined with Deucravacitinib.
Deutetrabenazine	The metabolism of Olaparib can be decreased when combined with Deutetrabenazine.
Dexamethasone	The metabolism of Olaparib can be increased when combined with Dexamethasone.
Dexamethasone ac	The metabolism of Olaparib can be increased when combined with Dexamethasone acetate.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Olaparib.
Dextran	The risk or severity of bleeding can be increased when Dextran is combined with Olaparib.
Dextromethorphan	The metabolism of Olaparib can be decreased when combined with Dextromethorphan.
Dextropropoxyph	The metabolism of Olaparib can be decreased when combined with Dextropropoxyphene.
Diazepam	The metabolism of Olaparib can be decreased when combined with Diazepam.
Dicloxacillin	The metabolism of Olaparib can be increased when combined with Dicloxacillin.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Olaparib.
Diethylstilbestrol	The metabolism of Olaparib can be decreased when combined with Diethylstilbestrol.
Difluocortolone	The metabolism of Olaparib can be increased when combined with Difluocortolone.
Digitoxin	The metabolism of Digitoxin can be decreased when combined with Olaparib.
Dihydroergocornine	The metabolism of Olaparib can be decreased when combined with Dihydroergocornine.
Dihydroergocristine	The metabolism of Olaparib can be decreased when combined with Dihydroergocristine.
Dihydroergotamine	The metabolism of Dihydroergotamine can be decreased when combined with Olaparib.
Diltiazem	The metabolism of Olaparib can be decreased when combined with Diltiazem.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Olaparib.
Dimethyl sulfoxide	The metabolism of Olaparib can be decreased when combined with Dimethyl sulfoxide.
Dinutuximab	The risk or severity of adverse effects can be increased when Olaparib is combined with Dinutuximab.
Diosmin	The metabolism of Olaparib can be decreased when combined with Diosmin.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Diphenhydramine.
Dipyridamole	The risk or severity of bleeding can be increased when Dipyridamole is combined with Olaparib.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Olaparib is combined with Diroximel fumarate.
Disulfiram	The metabolism of Olaparib can be decreased when combined with Disulfiram.
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Olaparib.
Dofetilide	The metabolism of Dofetilide can be decreased when combined with Olaparib.
Domperidone	The metabolism of Olaparib can be decreased when combined with Domperidone.
Doravirine	The metabolism of Olaparib can be decreased when combined with Doravirine.
Doxazosin	The metabolism of Olaparib can be decreased when combined with Doxazosin.
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Olaparib.
Dronabinol	The serum concentration of Dronabinol can be increased when it is combined with Olaparib.
Dronedarone	The metabolism of Olaparib can be decreased when combined with Dronedarone.
Drospirenone	The metabolism of Olaparib can be decreased when combined with Drospirenone.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Olaparib.
Dutasteride	The metabolism of Olaparib can be decreased when combined with Dutasteride.
Duvelisib	The metabolism of Olaparib can be decreased when combined with Duvelisib.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Dyclonine.
Ebastine	The metabolism of Olaparib can be decreased when combined with Ebastine.
Ebola Zaire vacci	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Olaparib.
Echinacea	The metabolism of Olaparib can be increased when combined with Echinacea.
Eculizumab	The risk or severity of adverse effects can be increased when Eculizumab is combined with Olaparib.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Olaparib.
Edoxaban	The risk or severity of bleeding can be increased when Edoxaban is combined with Olaparib.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Olaparib.
Efavirenz	The metabolism of Olaparib can be increased when combined with Efavirenz.
Elbasvir	The metabolism of Olaparib can be decreased when combined with Elbasvir.
Elexacaftor	The metabolism of Olaparib can be decreased when combined with Elexacaftor.
Eliglustat	The metabolism of Eliglustat can be decreased when combined with Olaparib.
Elvitegravir	The metabolism of Olaparib can be decreased when combined with Elvitegravir.
Emapalumab	The metabolism of Olaparib can be increased when combined with Emapalumab.
Enasidenib	The metabolism of Olaparib can be increased when combined with Enasidenib.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Olaparib.
Entrectinib	The metabolism of Entrectinib can be decreased when combined with Olaparib.
Enzalutamide	The metabolism of Olaparib can be increased when combined with Enzalutamide.
Epinephrine	The metabolism of Olaparib can be decreased when combined with Epinephrine.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Olaparib.
Eplerenone	The metabolism of Olaparib can be decreased when combined with Eplerenone.
Epoprostenol	The risk or severity of bleeding can be increased when Epoprostenol is combined with Olaparib.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Olaparib.
Erdafitinib	The metabolism of Erdafitinib can be decreased when combined with Olaparib.
Ergotamine	The metabolism of Olaparib can be decreased when combined with Ergotamine.
Eribulin	The risk or severity of adverse effects can be increased when Eribulin is combined with Olaparib.
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Olaparib.
Erythromycin	The metabolism of Olaparib can be decreased when combined with Erythromycin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Olaparib.
Esketamine	The metabolism of Olaparib can be increased when combined with Esketamine.
Eslicarbazepine	The metabolism of Olaparib can be increased when combined with Eslicarbazepine.
Eslicarbazepine ac	The metabolism of Olaparib can be increased when combined with Eslicarbazepine acetate.
Estetrol	The metabolism of Olaparib can be decreased when combined with Estetrol.
Estradiol	The metabolism of Olaparib can be decreased when combined with Estradiol.
Estradiol acetate	The metabolism of Olaparib can be increased when combined with Estradiol acetate.
Estradiol benzoate	The metabolism of Olaparib can be increased when combined with Estradiol benzoate.
Estradiol cypionate	The metabolism of Olaparib can be increased when combined with Estradiol cypionate.
Estradiol dienanthate	The metabolism of Olaparib can be increased when combined with Estradiol dienanthate.
Estradiol valerate	The metabolism of Olaparib can be increased when combined with Estradiol valerate.
Estramustine	The risk or severity of adverse effects can be increased when Estramustine is combined with Olaparib.
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Olaparib.
Etanercept	The metabolism of Olaparib can be increased when combined with Etanercept.
Ethambutol	The metabolism of Olaparib can be decreased when combined with Ethambutol.
Ethanol	The metabolism of Olaparib can be increased when combined with Ethanol.
Ethinylestradiol	The metabolism of Olaparib can be decreased when combined with Ethinylestradiol.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Etidocaine.
Etoposide	The metabolism of Etoposide can be decreased when combined with Olaparib.
Etoricoxib	The metabolism of Olaparib can be decreased when combined with Etoricoxib.
Etravirine	The metabolism of Olaparib can be increased when combined with Etravirine.
Everolimus	The metabolism of Everolimus can be decreased when combined with Olaparib.
Famtozinameran	The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Olaparib.
Felbamate	The metabolism of Olaparib can be increased when combined with Felbamate.
Felodipine	The metabolism of Olaparib can be decreased when combined with Felodipine.
Fenofibrate	The metabolism of Olaparib can be decreased when combined with Fenofibrate.

You Might Also Read Infliximab; Uses, Dosage, Side Effects, Drug Interactions

Fexinidazole	The metabolism of Olaparib can be decreased when combined with Fexinidazole.
Filgotinib	The risk or severity of adverse effects can be increased when Olaparib is combined with Filgotinib.
Finasteride	The metabolism of Olaparib can be decreased when combined with Finasteride.
Finerenone	The serum concentration of Finerenone can be increased when it is combined with Olaparib.
Fingolimod	Olaparib may increase the immunosuppressive activities of Fingolimod.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Olaparib.
Flucloxacillin	The metabolism of Olaparib can be increased when combined with Flucloxacillin.
Fluconazole	The metabolism of Olaparib can be decreased when combined with Fluconazole.
Flucytosine	The risk or severity of adverse effects can be increased when Flucytosine is combined with Olaparib.
Fludarabine	The risk or severity of adverse effects can be increased when Fludarabine is combined with Olaparib.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Olaparib.
Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Olaparib.
Flunisolide	The metabolism of Olaparib can be increased when combined with Flunisolide.
Fluocinolone ac	The metabolism of Olaparib can be increased when combined with Fluocinolone acetonide.
Fluocinonide	The metabolism of Olaparib can be increased when combined with Fluocinonide.
Fluocortolone	The metabolism of Olaparib can be increased when combined with Fluocortolone.
Fluorometholone	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Olaparib.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Olaparib.
Fluoxetine	The metabolism of Olaparib can be decreased when combined with Fluoxetine.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Olaparib.
Fluprednisolone	The risk or severity of adverse effects can be increased when Olaparib is combined with Fluprednisolone.
Flutamide	The metabolism of Olaparib can be decreased when combined with Flutamide.
Fluticasone	The metabolism of Olaparib can be increased when combined with Fluticasone.
Fluticasone furoate	The metabolism of Olaparib can be decreased when combined with Fluticasone furoate.
Fluticasone prop	The metabolism of Olaparib can be decreased when combined with Fluticasone propionate.
Fluvastatin	The metabolism of Olaparib can be decreased when combined with Fluvastatin.
Fluvoxamine	The metabolism of Olaparib can be decreased when combined with Fluvoxamine.
Fondaparinux	The risk or severity of bleeding can be increased when Fondaparinux is combined with Olaparib.
Formestane	The metabolism of Olaparib can be increased when combined with Formestane.
Fosamprenavir	The metabolism of Olaparib can be decreased when combined with Fosamprenavir.
Fosaprepitant	The metabolism of Olaparib can be increased when combined with Fosaprepitant.
Fosnetupitant	The metabolism of Olaparib can be decreased when combined with Fosnetupitant.
Fosphenytoin	The metabolism of Olaparib can be increased when combined with Fosphenytoin.
Fostamatinib	The metabolism of Olaparib can be decreased when combined with Fostamatinib.
Fusidic acid	The metabolism of Olaparib can be decreased when combined with Fusidic acid.
Gallium nitrate	The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Olaparib.
Gefitinib	The metabolism of Olaparib can be decreased when combined with Gefitinib.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Olaparib.
Gemtuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaparib.
Gilteritinib	The metabolism of Olaparib can be decreased when combined with Gilteritinib.
Ginkgo biloba	The metabolism of Olaparib can be decreased when combined with Ginkgo biloba.
Glatiramer	The risk or severity of adverse effects can be increased when Glatiramer is combined with Olaparib.
Glecaprevir	The metabolism of Olaparib can be decreased when combined with Glecaprevir.
Glyburide	The metabolism of Olaparib can be decreased when combined with Glyburide.
Glycerol pheny	The metabolism of Olaparib can be increased when combined with Glycerol phenylbutyrate.
Golimumab	The metabolism of Olaparib can be increased when combined with Golimumab.
Griseofulvin	The metabolism of Olaparib can be increased when combined with Griseofulvin.
Guselkumab	The risk or severity of adverse effects can be increased when Olaparib is combined with Guselkumab.
Haemophilus	The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Olaparib.
Halofantrine	The metabolism of Olaparib can be decreased when combined with Halofantrine.
Haloperidol	The metabolism of Olaparib can be decreased when combined with Haloperidol.
Heparin	The risk or severity of bleeding can be increased when Heparin is combined with Olaparib.
Hepatitis A Vaccine	The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Olaparib.
Hepatitis B Vacci	The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Olaparib.
Human adenoviru	The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Olaparib.
Hydralazine	The metabolism of Olaparib can be decreased when combined with Hydralazine.
Hydrochlorothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Olaparib.
Hydrocortamate	The metabolism of Olaparib can be increased when combined with Hydrocortamate.
Hydrocortisone	The metabolism of Olaparib can be increased when combined with Hydrocortisone.
Hydrocortisone acet	The metabolism of Olaparib can be increased when combined with Hydrocortisone acetate.
Hydrocortisone but	The metabolism of Olaparib can be increased when combined with Hydrocortisone butyrate.
Hydrocortisone cyp	The metabolism of Olaparib can be decreased when combined with Hydrocortisone cypionate.
Hydrocortisone phos	The metabolism of Olaparib can be decreased when combined with Hydrocortisone phosphate.
Hydrocortisone succ	The metabolism of Olaparib can be increased when combined with Hydrocortisone succinate.
Hydroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Olaparib.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Olaparib.
Hydroxyprogesterone	The metabolism of Olaparib can be decreased when combined with Hydroxyprogesterone caproate.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Olaparib.
Hydroxyzine	The metabolism of Olaparib can be decreased when combined with Hydroxyzine.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaparib.
Ibrutinib	The metabolism of Ibrutinib can be decreased when combined with Olaparib.
Icosapent ethyl	The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Olaparib.
Idarubicin	The risk or severity of adverse effects can be increased when Idarubicin is combined with Olaparib.
Idelalisib	The metabolism of Idelalisib can be decreased when combined with Olaparib.
Ifosfamide	The metabolism of Olaparib can be increased when combined with Ifosfamide.
Iloperidone	The metabolism of Iloperidone can be decreased when combined with Olaparib.
Iloprost	The risk or severity of bleeding can be increased when Iloprost is combined with Olaparib.
Imatinib	The serum concentration of Olaparib can be increased when it is combined with Imatinib.
Indinavir	The metabolism of Olaparib can be decreased when combined with Indinavir.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Olaparib.
Inebilizumab	The risk or severity of infection can be increased when Olaparib is combined with Inebilizumab.
Infigratinib	The metabolism of Olaparib can be decreased when combined with Infigratinib.
Infliximab	The metabolism of Olaparib can be increased when combined with Infliximab.

Irbesartan	The metabolism of Olaparib can be decreased when combined with Irbesartan.
Irinotecan	The metabolism of Irinotecan can be decreased when combined with Olaparib.
Isavuconazole	The metabolism of Olaparib can be decreased when combined with Isavuconazole.
Isavuconazonium	The metabolism of Olaparib can be decreased when combined with Isavuconazonium.
Isoniazid	The metabolism of Olaparib can be decreased when combined with Isoniazid.
Isradipine	The metabolism of Olaparib can be decreased when combined with Isradipine.
Istradefylline	The metabolism of Olaparib can be decreased when combined with Istradefylline.
Itraconazole	The metabolism of Olaparib can be decreased when combined with Itraconazole.
Ivacaftor	The metabolism of Olaparib can be decreased when combined with Ivacaftor.
Ivosidenib	The metabolism of Olaparib can be increased when combined with Ivosidenib.
Ixabepilone	The metabolism of Ixabepilone can be decreased when combined with Olaparib.
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Olaparib.
Ixekizumab	The risk or severity of adverse effects can be increased when Olaparib is combined with Ixekizumab.
Janssen COVID-19	The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Olaparib.
Jap encephalitis	The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Olaparib.
Ketazolam	The metabolism of Olaparib can be decreased when combined with Ketazolam.
Ketoconazole	The metabolism of Olaparib can be decreased when combined with Ketoconazole.
Lacosamide	The metabolism of Olaparib can be decreased when combined with Lacosamide.
Lanreotide	The metabolism of Olaparib can be decreased when combined with Lanreotide.
Lapatinib	The metabolism of Olaparib can be decreased when combined with Lapatinib.
Lefamulin	The serum concentration of Olaparib can be increased when it is combined with Lefamulin.
Leflunomide	The risk or severity of adverse effects can be increased when Olaparib is combined with Leflunomide.
Lemborexant	The metabolism of Olaparib can be decreased when combined with Lemborexant.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Olaparib.
Lepirudin	The risk or severity of bleeding can be increased when Lepirudin is combined with Olaparib.
Lercanidipine	The metabolism of Olaparib can be decreased when combined with Lercanidipine.
Lesinurad	The metabolism of Olaparib can be increased when combined with Lesinurad.
Letermovir	The metabolism of Olaparib can be decreased when combined with Letermovir.
Levacetylmet	The metabolism of Levacetylmethadol can be decreased when combined with Olaparib.
Levamlodipine	The serum concentration of Levamlodipine can be increased when it is combined with Olaparib.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Levobupivacaine.
Levoketoconazole	The metabolism of Olaparib can be decreased when combined with Levoketoconazole.
Levonorgestrel	The metabolism of Olaparib can be decreased when combined with Levonorgestrel.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Lidocaine.
Linagliptin	The metabolism of Olaparib can be decreased when combined with Linagliptin.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Olaparib.
Lipegfilgrastim	Olaparib may increase the myelosuppressive activities of Lipegfilgrastim.
Lomitapide	The metabolism of Lomitapide can be decreased when combined with Olaparib.
Lomustine	The risk or severity of adverse effects can be increased when Lomustine is combined with Olaparib.
Lonafarnib	The metabolism of Olaparib can be decreased when combined with Lonafarnib.
Lopinavir	The metabolism of Olaparib can be decreased when combined with Lopinavir.
Lorlatinib	The metabolism of Olaparib can be increased when combined with Lorlatinib.
Losartan	The metabolism of Olaparib can be decreased when combined with Losartan.
Lovastatin	The metabolism of Olaparib can be decreased when combined with Lovastatin.
Lumacaftor	The metabolism of Olaparib can be increased when combined with Lumacaftor.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Olaparib.
Manidipine	The metabolism of Olaparib can be decreased when combined with Manidipine.
Mavacamten	The serum concentration of Olaparib can be decreased when it is combined with Mavacamten.
Measles virus	The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Olaparib.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Olaparib.
Medroxyprog	The metabolism of Olaparib can be increased when combined with Medroxyprogesterone acetate.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Meloxicam.
Melphalan	The risk or severity of adverse effects can be increased when Melphalan is combined with Olaparib.
Meningococcal	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Olaparib.
Meperidine	The metabolism of Olaparib can be decreased when combined with Meperidine.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Mepolizumab is combined with Olaparib.
Meprednisone	The metabolism of Olaparib can be increased when combined with Meprednisone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Olaparib.
Metamizole	The risk or severity of myelosuppression can be increased when Metamizole is combined with Olaparib.
Methadone	The metabolism of Olaparib can be decreased when combined with Methadone.
Methimazole	The metabolism of Olaparib can be decreased when combined with Methimazole.
Methotrexate	The metabolism of Methotrexate can be decreased when combined with Olaparib.
Methoxy polye	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Olaparib.
Methylene blue	The metabolism of Olaparib can be decreased when combined with Methylene blue.
Methylergometrine	The metabolism of Olaparib can be decreased when combined with Methylergometrine.
Methylphenobarbital	The metabolism of Olaparib can be increased when combined with Methylphenobarbital.
Methylprednisolone	The metabolism of Olaparib can be increased when combined with Methylprednisolone.
Methylprednisone	The metabolism of Olaparib can be decreased when combined with Methylprednisone.
Methysergide	The metabolism of Olaparib can be decreased when combined with Methysergide.
Metreleptin	The metabolism of Olaparib can be increased when combined with Metreleptin.
Metronidazole	The metabolism of Olaparib can be decreased when combined with Metronidazole.
Metyrapone	The metabolism of Olaparib can be increased when combined with Metyrapone.
Miconazole	The metabolism of Olaparib can be decreased when combined with Miconazole.
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Olaparib.
Midostaurin	The metabolism of Olaparib can be increased when combined with Midostaurin.
Mifepristone	The metabolism of Olaparib can be increased when combined with Mifepristone.
Milnacipran	The metabolism of Olaparib can be decreased when combined with Milnacipran.
Miocamycin	The metabolism of Olaparib can be decreased when combined with Miocamycin.
Mirtazapine	The metabolism of Olaparib can be decreased when combined with Mirtazapine.
Mitapivat	The metabolism of Olaparib can be increased when combined with Mitapivat.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Olaparib.
Mitotane	The metabolism of Olaparib can be increased when combined with Mitotane.
Mitoxantrone	The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Olaparib.
Mobocertinib	The serum concentration of Olaparib can be decreased when it is combined with Mobocertinib.
Modafinil	The metabolism of Olaparib can be increased when combined with Modafinil.
Moderna COVID	The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Olaparib.
Modified vaccinia	The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Olaparib.
Mometasone fur	The metabolism of Olaparib can be increased when combined with Mometasone furoate.
Monomethyl fum	The risk or severity of adverse effects can be increased when Olaparib is combined with Monomethyl fumarate.
Mosunetuzumab	The metabolism of Olaparib can be decreased when combined with Mosunetuzumab.
Mumps virus	The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Olaparib.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Olaparib.
Mycophenolate mo	The metabolism of Olaparib can be decreased when combined with Mycophenolate mofetil.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Olaparib.
Nadroparin	The risk or severity of bleeding can be increased when Nadroparin is combined with Olaparib.
Nafcillin	The metabolism of Olaparib can be increased when combined with Nafcillin.

Natalizumab	The risk or severity of adverse effects can be increased when Olaparib is combined with Natalizumab.
Nateglinide	The metabolism of Olaparib can be decreased when combined with Nateglinide.
Nefazodone	The metabolism of Olaparib can be decreased when combined with Nefazodone.
Nelarabine	The risk or severity of adverse effects can be increased when Nelarabine is combined with Olaparib.
Nelfinavir	The metabolism of Olaparib can be decreased when combined with Nelfinavir.
Neratinib	The metabolism of Neratinib can be decreased when combined with Olaparib.
Netupitant	The metabolism of Olaparib can be decreased when combined with Netupitant.
Nevirapine	The metabolism of Olaparib can be decreased when combined with Nevirapine.
Niacin	The metabolism of Olaparib can be decreased when combined with Niacin.
Nicardipine	The metabolism of Olaparib can be decreased when combined with Nicardipine.
Nifedipine	The metabolism of Olaparib can be decreased when combined with Nifedipine.
Nilotinib	The metabolism of Olaparib can be decreased when combined with Nilotinib.
Nilvadipine	The metabolism of Olaparib can be decreased when combined with Nilvadipine.
Nimesulide	The risk or severity of bleeding can be increased when Nimesulide is combined with Olaparib.
Nintedanib	The metabolism of Olaparib can be decreased when combined with Nintedanib.
Nisoldipine	The metabolism of Olaparib can be decreased when combined with Nisoldipine.
Nitrendipine	The metabolism of Olaparib can be decreased when combined with Nitrendipine.
Norethisterone	The metabolism of Olaparib can be decreased when combined with Norethisterone.
Norgestimate	The metabolism of Olaparib can be increased when combined with Norgestimate.
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Olaparib.
Noscapine	The metabolism of Olaparib can be decreased when combined with Noscapine.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Olaparib.
Obinutuzumab	The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Olaparib.
Ocrelizumab	The risk or severity of adverse effects can be increased when Olaparib is combined with Ocrelizumab.
Octreotide	The serum concentration of Olaparib can be increased when it is combined with Octreotide.
Ofatumumab	The risk or severity of adverse effects can be increased when Ofatumumab is combined with Olaparib.
Ondansetron	The metabolism of Olaparib can be decreased when combined with Ondansetron.
Oritavancin	The metabolism of Olaparib can be increased when combined with Oritavancin.
Orphenadrine	The metabolism of Olaparib can be decreased when combined with Orphenadrine.
Osilodrostat	The metabolism of Olaparib can be decreased when combined with Osilodrostat.
Osimertinib	The metabolism of Osimertinib can be decreased when combined with Olaparib.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Olaparib.
Oxcarbazepine	The metabolism of Olaparib can be increased when combined with Oxcarbazepine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Oxetacaine.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Oxybuprocaine.
Oxybutynin	The metabolism of Olaparib can be decreased when combined with Oxybutynin.
Oxycodone	The metabolism of Olaparib can be decreased when combined with Oxycodone.
Ozanimod	The risk or severity of adverse effects can be increased when Olaparib is combined with Ozanimod.
Paclitaxel	The metabolism of Olaparib can be increased when combined with Paclitaxel.
Pacritinib	The serum concentration of Olaparib can be increased when it is combined with Pacritinib.
Palbociclib	The metabolism of Olaparib can be decreased when combined with Palbociclib.
Palifermin	The therapeutic efficacy of Palifermin can be decreased when used in combination with Olaparib.
Paliperidone	The metabolism of Olaparib can be decreased when combined with Paliperidone.
Panobinostat	The metabolism of Panobinostat can be decreased when combined with Olaparib.
Paritaprevir	The metabolism of Olaparib can be decreased when combined with Paritaprevir.
Parnaparin	The risk or severity of bleeding can be increased when Parnaparin is combined with Olaparib.
Pasireotide	The metabolism of Olaparib can be decreased when combined with Pasireotide.
Pazopanib	The metabolism of Olaparib can be decreased when combined with Pazopanib.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Olaparib.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Olaparib is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Olaparib.
Peginterferon alf	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Olaparib.
Peginterferon a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Olaparib.
Peginterferon	The risk or severity of adverse effects can be increased when Olaparib is combined with Peginterferon beta-1a.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Olaparib.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Olaparib.
Pentamidine	The metabolism of Olaparib can be decreased when combined with Pentamidine.
Pentobarbital	The metabolism of Olaparib can be increased when combined with Pentobarbital.
Pentosan polysu	The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Olaparib.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Olaparib.
Pentoxifylline	The risk or severity of bleeding can be increased when Pentoxifylline is combined with Olaparib.
Perampanel	The metabolism of Olaparib can be increased when combined with Perampanel.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Olaparib.
Pexidartinib	The metabolism of Pexidartinib can be decreased when combined with Olaparib.
Phenindione	The risk or severity of bleeding can be increased when Phenindione is combined with Olaparib.
Phenobarbital	The metabolism of Olaparib can be increased when combined with Phenobarbital.
Phenol	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Phenol.
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Olaparib.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Olaparib.
Phenylbutazone	The metabolism of Olaparib can be increased when combined with Phenylbutazone.
Phenytoin	The metabolism of Olaparib can be increased when combined with Phenytoin.
Pimavanserin	The metabolism of Olaparib can be decreased when combined with Pimavanserin.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Olaparib.
Pimozide	The metabolism of Pimozide can be decreased when combined with Olaparib.
Piperaquine	The metabolism of Olaparib can be decreased when combined with Piperaquine.
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Olaparib.
Pirtobrutinib	The metabolism of Olaparib can be decreased when combined with Pirtobrutinib.
Pitolisant	The serum concentration of Olaparib can be decreased when it is combined with Pitolisant.
Polythiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Olaparib.
Pomalidomide	The metabolism of Pomalidomide can be decreased when combined with Olaparib.
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Olaparib.
Ponesimod	The metabolism of Olaparib can be decreased when combined with Ponesimod.
Posaconazole	The metabolism of Olaparib can be decreased when combined with Posaconazole.
Pralatrexate	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Olaparib.
Pralsetinib	The metabolism of Olaparib can be increased when combined with Pralsetinib.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Pramocaine.
Prasugrel	The risk or severity of bleeding can be increased when Prasugrel is combined with Olaparib.
Praziquantel	The metabolism of Olaparib can be decreased when combined with Praziquantel.
Prednisolone	The metabolism of Olaparib can be increased when combined with Prednisolone.
Prednisolone ac	The metabolism of Olaparib can be increased when combined with Prednisolone acetate.
Prednisolone phosphate	The metabolism of Olaparib can be increased when combined with Prednisolone phosphate.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Olaparib.
Prednisone ace	The metabolism of Olaparib can be increased when combined with Prednisone acetate.
Pretomanid	The metabolism of Olaparib can be decreased when combined with Pretomanid.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Prilocaine.
Primaquine	The metabolism of Olaparib can be decreased when combined with Primaquine.
Primidone	The metabolism of Olaparib can be increased when combined with Primidone.
Probenecid	The metabolism of Olaparib can be increased when combined with Probenecid.
Procaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Procaine.
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Olaparib.

You Might Also Read Barosmin - Uses, Dosage, Side Effects

Progesterone	The metabolism of Olaparib can be decreased when combined with Progesterone.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Proparacaine.
Propofol	The metabolism of Olaparib can be decreased when combined with Propofol.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Propoxycaine.
Propranolol	The metabolism of Olaparib can be decreased when combined with Propranolol.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Olaparib.
Protein C	The risk or severity of bleeding can be increased when Protein C is combined with Olaparib.
Protein S human	The risk or severity of bleeding can be increased when Protein S human is combined with Olaparib.
Prucalopride	The metabolism of Prucalopride can be decreased when combined with Olaparib.
Quetiapine	The metabolism of Olaparib can be decreased when combined with Quetiapine.
Quinidine	The metabolism of Olaparib can be decreased when combined with Quinidine.
Quinine	The metabolism of Olaparib can be increased when combined with Quinine.
Quinupristin	The metabolism of Olaparib can be decreased when combined with Quinupristin.
Rabies immune	The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Olaparib.
Rabie antigen, A	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Olaparib.
Rabie antigen, B	The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Olaparib.
Raloxifene	The metabolism of Olaparib can be decreased when combined with Raloxifene.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Olaparib.
Ranolazine	The metabolism of Olaparib can be decreased when combined with Ranolazine.
Ravulizumab	The risk or severity of adverse effects can be increased when Olaparib is combined with Ravulizumab.
Regorafenib	The metabolism of Regorafenib can be decreased when combined with Olaparib.
Relugolix	The metabolism of Olaparib can be decreased when combined with Relugolix.
Remdesivir	The metabolism of Olaparib can be decreased when combined with Remdesivir.
Reserpine	The metabolism of Olaparib can be increased when combined with Reserpine.
Retapamulin	The metabolism of Retapamulin can be decreased when combined with Olaparib.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Olaparib.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Olaparib.
Ribociclib	The metabolism of Olaparib can be decreased when combined with Ribociclib.
Rifabutin	The metabolism of Olaparib can be increased when combined with Rifabutin.
Rifampicin	The metabolism of Olaparib can be increased when combined with Rifampicin.
Rifamycin	The metabolism of Olaparib can be increased when combined with Rifamycin.
Rifapentine	The metabolism of Olaparib can be increased when combined with Rifapentine.
Rilonacept	The metabolism of Olaparib can be increased when combined with Rilonacept.
Rilpivirine	The metabolism of Olaparib can be decreased when combined with Rilpivirine.
Rimexolone	The metabolism of Olaparib can be increased when combined with Rimexolone.
Risankizumab	The risk or severity of adverse effects can be increased when Olaparib is combined with Risankizumab.
Risperidone	The metabolism of Olaparib can be decreased when combined with Risperidone.
Ritonavir	The metabolism of Olaparib can be decreased when combined with Ritonavir.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Olaparib.
Rivaroxaban	The metabolism of Olaparib can be decreased when combined with Rivaroxaban.
Rofecoxib	The metabolism of Olaparib can be increased when combined with Rofecoxib.
Roflumilast	The serum concentration of Roflumilast can be increased when it is combined with Olaparib.
Romidepsin	The metabolism of Romidepsin can be decreased when combined with Olaparib.
Ropeginterfe	The risk or severity of adverse effects can be increased when Olaparib is combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Ropivacaine.
Rosuvastatin	The metabolism of Olaparib can be decreased when combined with Rosuvastatin.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Olaparib.
Roxithromycin	The metabolism of Olaparib can be decreased when combined with Roxithromycin.
Rubella virus va	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Olaparib.
Rucaparib	The metabolism of Olaparib can be decreased when combined with Rucaparib.
Rufinamide	The metabolism of Olaparib can be increased when combined with Rufinamide.
Ruxolitinib	The metabolism of Ruxolitinib can be decreased when combined with Olaparib.
Salmeterol	The metabolism of Olaparib can be decreased when combined with Salmeterol.
Saquinavir	The metabolism of Olaparib can be decreased when combined with Saquinavir.
Sarilumab	The metabolism of Olaparib can be increased when combined with Sarilumab.
Satralizumab	The serum concentration of Olaparib can be decreased when it is combined with Satralizumab.
Saxagliptin	The metabolism of Olaparib can be decreased when combined with Saxagliptin.
Secobarbital	The metabolism of Olaparib can be increased when combined with Secobarbital.
Secukinumab	The metabolism of Olaparib can be increased when combined with Secukinumab.
Selumetinib	The metabolism of Olaparib can be decreased when combined with Selumetinib.
Sildenafil	The metabolism of Olaparib can be decreased when combined with Sildenafil.
Siltuximab	The metabolism of Olaparib can be increased when combined with Siltuximab.
Simeprevir	The metabolism of Olaparib can be decreased when combined with Simeprevir.
Simvastatin	The metabolism of Olaparib can be decreased when combined with Simvastatin.
Siponimod	The metabolism of Siponimod can be decreased when combined with Olaparib.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Olaparib.
Sirolimus	The metabolism of Sirolimus can be decreased when combined with Olaparib.
Sitaxentan	The metabolism of Olaparib can be decreased when combined with Sitaxentan.
Smallpox (Vaccini	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Olaparib.
Sodium citrate	The risk or severity of bleeding can be increased when Sodium citrate is combined with Olaparib.
Somatostatin	The metabolism of Olaparib can be decreased when combined with Somatostatin.
Somatrogon	The metabolism of Olaparib can be increased when combined with Somatrogon.
Sonidegib	The metabolism of Sonidegib can be decreased when combined with Olaparib.
Sorafenib	The metabolism of Sorafenib can be decreased when combined with Olaparib.
Sotorasib	The serum concentration of Olaparib can be decreased when it is combined with Sotorasib.
Spesolimab	The risk or severity of adverse effects can be increased when Olaparib is combined with Spesolimab.
St. John’s Wort	The metabolism of Olaparib can be increased when combined with St. John’s Wort.
Stiripentol	The metabolism of Olaparib can be decreased when combined with Stiripentol.
Streptokinase	The risk or severity of bleeding can be increased when Streptokinase is combined with Olaparib.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Olaparib.
Sulfamethoxazole	The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Olaparib.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Olaparib.
Sulfinpyrazone	The metabolism of Olaparib can be increased when combined with Sulfinpyrazone.
Sulodexide	The risk or severity of bleeding can be increased when Sulodexide is combined with Olaparib.
Sunitinib	The metabolism of Sunitinib can be decreased when combined with Olaparib.
Sutimlimab	The risk or severity of adverse effects can be increased when Olaparib is combined with Sutimlimab.
Suvorexant	The metabolism of Olaparib can be decreased when combined with Suvorexant.
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Olaparib.
Tadalafil	The metabolism of Olaparib can be decreased when combined with Tadalafil.
Tamoxifen	The metabolism of Olaparib can be increased when combined with Tamoxifen.
Tasimelteon	The metabolism of Olaparib can be decreased when combined with Tasimelteon.
Tazemetostat	The metabolism of Olaparib can be decreased when combined with Tazemetostat.
Tecovirimat	The metabolism of Olaparib can be increased when combined with Tecovirimat.
Tedizolid phosp	The risk or severity of myelosuppression can be increased when Tedizolid phosphate is combined with Olaparib.
Tegafur	The metabolism of Tegafur can be decreased when combined with Olaparib.
Telaprevir	The metabolism of Olaparib can be decreased when combined with Telaprevir.
Telithromycin	The metabolism of Olaparib can be decreased when combined with Telithromycin.
Telotristat ethyl	The serum concentration of Olaparib can be decreased when it is combined with Telotristat ethyl.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Olaparib.
Temsirolimus	The metabolism of Temsirolimus can be decreased when combined with Olaparib.

Tenecteplase	The risk or severity of bleeding can be increased when Tenecteplase is combined with Olaparib.
Teniposide	The metabolism of Teniposide can be decreased when combined with Olaparib.
Tenofovir alafe	The metabolism of Olaparib can be decreased when combined with Tenofovir alafenamide.
Teprotumumab	The risk or severity of adverse effects can be increased when Teprotumumab is combined with Olaparib.
Terbinafine	The metabolism of Olaparib can be increased when combined with Terbinafine.
Terfenadine	The metabolism of Olaparib can be decreased when combined with Terfenadine.
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with Olaparib.
Testosterone	The metabolism of Olaparib can be increased when combined with Testosterone.
Testosterone cy	The metabolism of Olaparib can be decreased when combined with Testosterone cypionate.
Testosterone en	The metabolism of Olaparib can be decreased when combined with Testosterone enanthate.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Tetracaine.
Tetracycline	The metabolism of Olaparib can be decreased when combined with Tetracycline.
Tezacaftor	The metabolism of Olaparib can be decreased when combined with Tezacaftor.
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Olaparib.
Theophylline	The metabolism of Theophylline can be decreased when combined with Olaparib.
Thiamylal	The metabolism of Olaparib can be increased when combined with Thiamylal.
Thiotepa	The metabolism of Thiotepa can be decreased when combined with Olaparib.
Ticagrelor	The metabolism of Olaparib can be decreased when combined with Ticagrelor.
Tick-borne encep	The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Olaparib.
Ticlopidine	The risk or severity of bleeding can be increased when Ticlopidine is combined with Olaparib.
Tinzaparin	The risk or severity of bleeding can be increased when Tinzaparin is combined with Olaparib.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Olaparib.
Tipranavir	The metabolism of Olaparib can be decreased when combined with Tipranavir.
Tirofiban	The risk or severity of bleeding can be increased when Tirofiban is combined with Olaparib.
Tixocortol	The risk or severity of adverse effects can be increased when Olaparib is combined with Tixocortol.
Tocilizumab	The metabolism of Olaparib can be increased when combined with Tocilizumab.
Tofacitinib	The metabolism of Tofacitinib can be decreased when combined with Olaparib.
Tolvaptan	The metabolism of Tolvaptan can be decreased when combined with Olaparib.
Topiramate	The metabolism of Olaparib can be increased when combined with Topiramate.
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Olaparib.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Olaparib.
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Olaparib.
Tramadol	The metabolism of Tramadol can be decreased when combined with Olaparib.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Olaparib.
Trastuzumab e	The metabolism of Trastuzumab emtansine can be decreased when combined with Olaparib.
Trazodone	The metabolism of Olaparib can be decreased when combined with Trazodone.
Tretinoin	The metabolism of Olaparib can be decreased when combined with Tretinoin.
Triamcinolone	The metabolism of Olaparib can be increased when combined with Triamcinolone.
Triazolam	The metabolism of Olaparib can be decreased when combined with Triazolam.
Trichlormeth	The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Olaparib.
Triclabendazole	The metabolism of Olaparib can be decreased when combined with Triclabendazole.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Olaparib.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Olaparib.
Trilostane	The risk or severity of adverse effects can be increased when Trilostane is combined with Olaparib.
Troglitazone	The metabolism of Olaparib can be increased when combined with Troglitazone.
Troleandomycin	The metabolism of Olaparib can be decreased when combined with Troleandomycin.
Tucatinib	The metabolism of Tucatinib can be decreased when combined with Olaparib.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Olaparib.
Typhoid Vacci	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Olaparib.
Typhoid Vi pol	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Olaparib.
Ublituximab	The risk or severity of infection can be increased when Ublituximab is combined with Olaparib.
Ubrogepant	The serum concentration of Ubrogepant can be increased when it is combined with Olaparib.
Udenafil	The metabolism of Olaparib can be decreased when combined with Udenafil.
Upadacitinib	The risk or severity of adverse effects can be increased when Olaparib is combined with Upadacitinib.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Olaparib.
Valbenazine	The metabolism of Olaparib can be decreased when combined with Valbenazine.
Valproic acid	The metabolism of Olaparib can be decreased when combined with Valproic acid.
Vandetanib	The metabolism of Vandetanib can be decreased when combined with Olaparib.
Vardenafil	The metabolism of Vardenafil can be decreased when combined with Olaparib.
Varicella zoster v	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Olaparib.
Varicella zoster	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Olaparib.
Vedolizumab	The risk or severity of adverse effects can be increased when Vedolizumab is combined with Olaparib.
Vemurafenib	The metabolism of Olaparib can be increased when combined with Vemurafenib.
Venetoclax	The metabolism of Olaparib can be decreased when combined with Venetoclax.
Verapamil	The metabolism of Olaparib can be decreased when combined with Verapamil.
Vibrio cholerae	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Olaparib.
Vilanterol	The risk or severity of adverse effects can be increased when Olaparib is combined with Vilanterol.
Viloxazine	The metabolism of Olaparib can be decreased when combined with Viloxazine.
Vinblastine	The metabolism of Olaparib can be increased when combined with Vinblastine.
Vincristine	The metabolism of Vincristine can be decreased when combined with Olaparib.
Vindesine	The metabolism of Vindesine can be decreased when combined with Olaparib.
Vinflunine	The metabolism of Vinflunine can be decreased when combined with Olaparib.
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Olaparib.
Vitamin E	The metabolism of Olaparib can be increased when combined with Vitamin E.
Voclosporin	The risk or severity of adverse effects can be increased when Olaparib is combined with Voclosporin.
Vonoprazan	The metabolism of Olaparib can be decreased when combined with Vonoprazan.
Vorapaxar	The metabolism of Olaparib can be decreased when combined with Vorapaxar.
Voriconazole	The metabolism of Olaparib can be decreased when combined with Voriconazole.
Vorinostat	The risk or severity of adverse effects can be increased when Vorinostat is combined with Olaparib.
Vortioxetine	The metabolism of Olaparib can be decreased when combined with Vortioxetine.
Voxelotor	The serum concentration of Olaparib can be increased when it is combined with Voxelotor.
Warfarin	The serum concentration of Warfarin can be increased when it is combined with Olaparib.
Ximelagatran	The risk or severity of bleeding can be increased when Ximelagatran is combined with Olaparib.
Yellow fever vacci	The risk or severity of infection can be increased when Yellow fever vaccine is combined with Olaparib.
Zafirlukast	The metabolism of Olaparib can be decreased when combined with Zafirlukast.
Zaleplon	The metabolism of Olaparib can be decreased when combined with Zaleplon.
Zanubrutinib	The metabolism of Zanubrutinib can be decreased when combined with Olaparib.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Olaparib.
Zimelidine	The metabolism of Olaparib can be decreased when combined with Zimelidine.
Ziprasidone	The metabolism of Olaparib can be decreased when combined with Ziprasidone.
Zonisamide	The metabolism of Olaparib can be decreased when combined with Zonisamide.
Zopiclone	The metabolism of Zopiclone can be decreased when combined with Olaparib.
Zuclopenthixol	The metabolism of Olaparib can be decreased when combined with Zuclopenthixol.

Pregnancy and Lactation

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.

Pregnancy

Based on findings in animals and its mechanism of action [see Clinical Pharmacology (12.1)], Lynparza can cause fetal harm when administered to a pregnant woman. There are no available data on Lynparza use in pregnant women to inform the drug-associated risk. In an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and
embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 300 mg twice daily [see Data]. Apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2-4%; and the risk for spontaneous abortion is approximately 15-20% in clinically recognized pregnancies.

Lactation

No information is available on the clinical use of olaparib during breastfeeding. Because olaparib is 82% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during olaparib therapy and for one month after the last dose.

Why is this medication prescribed?

Olaparib is used alone or in combination with bevacizumab (Avastin) to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer in people who have completely responded or partially responded to their first or later chemotherapy treatments. Olaparib is also used to treat certain types of breast cancer that has spread to other parts of the body and has not improved or has worsened after treatment with other therapies. It is also used to treat certain types of early breast cancer in people who have already been treated with other chemotherapy treatments. Olaparib is also used to treat a certain type of prostate cancer that has spread to other parts of the body, no longer responds to medical or surgical treatments to lower testosterone levels, and has progressed after treatment with enzalutamide (Xtandi) or abiraterone (Yonsa, Zytiga). Olaparib is also used to treat ovarian cancer that has not improved or has worsened after treatment with at least three other therapies. Olaparib is also used to help maintain the response of a certain type of pancreatic cancer that has not spread or progressed after the first chemotherapy treatment. Olaparib is a polyadenosine 5′-diphosphoribose polymerase (PARP) enzyme inhibitor. It works by killing cancer cells.

How should this medicine be used?

Olaparib comes as a tablet to take by mouth twice daily with or without food. Try to space your doses about 12 hours apart. Take olaparib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take olaparib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole; do not crush chew, divide, or dissolve them.

Your doctor may decrease your dose of olaparib or tell you to stop taking olaparib for a period of time during your treatment. This will depend on how well the medication works for you and any side effects you may experience. Be sure to tell your doctor how you are feeling during your treatment with olaparib.

Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with olaparib. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (https://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) to obtain the Medication Guide.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking olaparib,

tell your doctor and pharmacist if you are allergic to olaparib, any other medications, or any of the ingredients in olaparib tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
The following herbal products may interact with olaparib: St. John’s wort. Be sure to let your doctor and pharmacist know that you are taking this medication before you start taking olaparib. Do not start this medication while taking olaparib without discussing it with your healthcare provider.
tell your doctor if you have or have ever had have lung or breathing problems, blood clots in your legs or lungs, or kidney or liver disease.
tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You may need to have a pregnancy test before starting treatment, You should not become pregnant while you are taking olaparib. You should use effective birth control to prevent pregnancy during your treatment with olaparib and for at least 6 months after your final dose. If you are a male and your partner can become pregnant, you should use effective birth control during your treatment with olaparib tablets and for 3 months after your final dose. Talk to your doctor about birth control methods that will work for you. If you become pregnant while taking olaparib, call your doctor immediately. Olaparib may harm the fetus.
tell your doctor if you are breastfeeding. Do not breastfeed while you are taking olaparib and for 1 month after your final dose.
you should know that you should not donate sperm while you are taking olaparib tablets and for 3 months after your final dose.

What special dietary instructions should I follow?

Do not eat grapefruit or Seville oranges (sometimes used in marmalades), or drink grapefruit juice or Seville orange juice while taking this medication.

What should I do if I forget a dose?

Skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

References

Olaparib – Uses, Dosage, Side Effects, Interactions

Mechanism of Action